FDA clears Chromogenix APC test
This article was originally published in Clinica
Executive Summary
The FDA has cleared Chromogenix' APC resistance test, Coatest, for sale in the US. APC resistance, an inability to shut down coagulation, is inherited in nine out of 10 cases and is also associated with ageing. The Molndal, Sweden-based company has been selling the test in Europe since 1993 where it is one of the company's main products. Chromogenix was granted a US patent for the test technique in August.